건선 : KOL 인사이트

What are the most effective treatments for psoriasis? How do current and pipeline therapies compare in terms of efficacy, safety, and cost-effectiveness? Leading KOLs evaluate Bimzelx (bimekizumab) as the most prescribed anti-IL17 due to its high efficacy and manageable side effects. Skyrizi (risankizumab) is identified as the leader in the anti-IL23 category, with Tremfya (guselkumab) also gaining traction for its cost-effectiveness. Johnson & Johnson's oral drug JNJ 77242113 shows significant potential to compete with existing treatments like Otezla (apremilast) and Sotyktu (deucravacitinib). Gain valuable insights into the current and future treatment paradigms for psoriasis, informed by expert opinions and detailed analysis.

Key brands covered in this report:

Key questions answered:

• How are current therapies for psoriasis used and perceived in terms of efficacy, tolerability, and ease of administration? How do they compare with pipeline options?
• Which drug class (anti-TNFs, anti-IL-12/23s, anti-IL-23s, anti-IL-17s and oral therapies) has the greatest potential to impact prescribing trends?
• How will the launch of biosimilars and the use of current, as well as newly approved/pipeline drugs, impact the psoriasis treatment paradigm in terms of patient segment, line of therapy, and preference?
• Are there any promising pipeline products and if so, how will they impact the current players in the market?
• Which clinical trials have the potential to impact prescribing trends, and how will the results affect the future treatment of psoriasis?
• How will the treatment landscape for psoriasis evolve in the future for each patient segment and line of therapy?
• What are KOLs' demands and expectations from the psoriasis market?

Table of Contents

Executive Summary

Research Objectives

Anti-TNF drugs

• Humira (adalimumab; AbbVie), Remicade (infliximab; Merck & Co./Johnson & Johnson Innovative Medicine), Enbrel (etanercept; Amgen), Cimzia (certolizumab; UCB)
  • Key insights summary

Anti-IL17 drugs

• Cosentyx (secukinumab; Novartis)
  • Key insights summary
• Taltz (ixekizumab; Lilly)
  • Key insights summary
• Siliq (US)/Kyntheum (EU)brodalumab; Ortho Dermatologics/LEO Pharma)
  • Key insights summary
• Bimzelx (bimekizumab; UCB)
  • Key insights summary

Anti-IL12/23 drugs

• Stelara (ustekinumab; Johnson & Johnson Innovative Medicine)
  • Key insights summary

Anti-IL23 drugs

• Tremfya (guselkumab; Johnson & Johnson Innovative Medicine)
  • Key insights summary
• Ilumya/Ilumetri (tildrakizumab; Sun Pharma/Almirall)
  • Key insights summary
• Skyrizi (risankizumab; AbbVie)
  • Key insights summary

PDE IV antagonists

• Otezla (apremilast; Amgen)
  • Key insights summary

Tyrosine Kinase 2 inhibitor

• Sotyktu (deucravacitinib; Bristol Myers Squibb)
  • Key insights summary

Pipeline drugs

• Piclidenoson (Can-Fite BioPharma)
  • Key insights summary
• Zasocitinib (TAK 279; Takeda)
  • Key insights summary
• JNJ 77242113 (Johnson & Johnson Innovative Medicine)
  • Key insights summary

Future outlook and treatment dynamics for management of psoriasis

• Key insights summary
  • Risankizumab, guselkumab and bimekizumab will pose strong competition to other drugs within the psoriasis treatment paradigm: biosimilars will enable early intervention with biologics

Appendix

KOL Bulletins